Literature DB >> 19688815

Determination of bencycloquidium bromide in dog plasma by liquid chromatography with electrospray ionization tandem mass spectrometry.

Bo Jiang1, Zourong Ruan, Honggang Lou, Xinwei Dong, Qiangmin Xie.   

Abstract

A rapid, selective and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method was developed and validated for determining bencycloquidium bromide (BCQB) in beagle dog plasma. The plasma sample was deproteinized with methanol which contained l-ethyl-bencycloquidium bromide as internal standard, and supernantant was assayed by LC-MS/MS. The chromatographic separation was performed on a Phenomenex C(18) column (100 x 2.0 mm, i.d., 3.0 microm) with a gradient programme mobile phase consisting of methanol and ammonium acetate (5 mm) containing 0.15% acetic acid and at a flow rate of 0.3 mL/min. Electrospray ionization in positive ion mode and selective reaction monitoring was used for the quantification of BCQB with a monitored transitions m/z 330.2 --> 142.1 for BCQB and m/z 344.2 --> 126.2 for IS. Validation results indicated that the lower limit of quantification was 0.05 ng/mL and the assay exhibited a linear range of 0.05-10.0 ng/mL and gave a correlation coefficient of 0.9998. The intra- and inter-run precisions of the assay were 1.7-4.6 and 3.2-15.6%, respectively, and the intra- and inter-day accuracies were -8.8 to 1.1 and -5.0 to 4.6%, respectively. The developed method was applied for the pharmacokinetic study of BCQB in beagle dogs following a single intranasal dose. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19688815     DOI: 10.1002/bmc.1316

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  4 in total

1.  In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5.

Authors:  Janvier Engelbert Agbokponto; Lingling Zhang; Linlin Hu; Hao Feng; Li Ding
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-11-26       Impact factor: 2.441

2.  Bencycloquidium bromide inhibits nasal hypersecretion in a rat model of allergic rhinitis.

Authors:  Rui Long; Yuanda Zhou; Jiangju Huang; Li Peng; Long Meng; Shenyin Zhu; Juan Li
Journal:  Inflamm Res       Date:  2015-02-18       Impact factor: 4.575

3.  Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.

Authors:  Fengjie Tian; Cuiyun Li; Xin Wang; Shuangxia Ren; Ning Li; Qi Liu; Sufeng Zhou; Yang Lu; Di Zhao; Xijing Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-20       Impact factor: 2.441

4.  Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.

Authors:  Luning Sun; Li Ding; Yongqing Wang; Wenjia Zhou; Zhengyu Yan; Weilin Sun; Hongwen Zhang; Ning Ou; Xiaoping Chen
Journal:  Drugs R D       Date:  2012-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.